SC
ABBV icon

Searle & Co’s AbbVie ABBV Stock Holding History

Searle & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
48,077
+300
+0.6% +$66.5K 2.63% 6
2025
Q4 		$10.9M Hold
47,777
– – 2.82% 5
2025
Q3 		$11.1M Buy
47,777
+200
+0.4% +$40.7K 2.93% 4
2025
Q2 		$8.83M Hold
47,577
– – 2.49% 6
2025
Q1 		$9.97M Buy
47,577
+200
+0.4% +$38.9K 2.84% 4
2024
Q4 		$8.42M Buy
47,377
+1,000
+2% +$184K 2.43% 5
2024
Q3 		$9.16M Sell
46,377
-4,897
-10% -$914K 2.28% 5
2024
Q2 		$8.79M Buy
51,274
+4,527
+10% +$750K 2.06% 9
2024
Q1 		$8.51M Hold
46,747
– – 2.17% 9
2023
Q4 		$7.24M Buy
46,747
+2,300
+5% +$335K 1.98% 11
2023
Q3 		$6.63M Hold
44,447
– – 2.25% 7
2023
Q2 		$6.65M Hold
44,447
– – 2.06% 9
2023
Q1 		$6.72M Hold
44,447
– – 2.2% 7
2022
Q4 		$7.18M Sell
44,447
-328
-0.7% -$50.3K 2.45% 6
2022
Q3 		$6.01M Hold
44,775
– – 2.31% 8
2022
Q2 		$6.86M Hold
44,775
– – 2.7% 6
2022
Q1 		$7.26M Sell
44,775
-248
-0.6% -$36K 2.68% 4
2021
Q4 		$6.1M Buy
45,023
+300
+0.7% +$35.4K 2.22% 6
2021
Q3 		$4.82M Hold
44,723
– – 1.98% 10
2021
Q2 		$5.04M Buy
44,723
+62
+0.1% +$6.98K 2.06% 9
2021
Q1 		$4.83M Buy
44,661
+100
+0.2% +$10.7K 2.16% 6
2020
Q4 		$4.78M Buy
44,561
+100
+0.2% +$9.61K 2.3% 8
2020
Q3 		$3.89M Hold
44,461
– – 2.12% 9
2020
Q2 		$4.37M Buy
44,461
+3,827
+9% +$337K 2.53% 6
2020
Q1 		$3.1M Buy
40,634
+3,500
+9% +$298K 2.2% 8
2019
Q4 		$3.29M Buy
37,134
+7,083
+24% +$588K 1.81% 16
2019
Q3 		$2.27M Buy
30,051
+67
+0.2% +$4.59K 1.34% 27
2019
Q2 		$2.18M Buy
29,984
+3,110
+12% +$244K 1.33% 27
2019
Q1 		$2.17M Hold
26,874
– – 1.35% 28
2018
Q4 		$2.48M Sell
26,874
-1,000
-4% -$87.9K 1.74% 17
2018
Q3 		$2.64M Hold
27,874
– – 1.55% 21
2018
Q2 		$2.58M Buy
27,874
+11,400
+69% +$1.11M 1.64% 21
2018
Q1 		$1.56M Buy
16,474
+1,157
+8% +$127K 1.01% 35
2017
Q4 		$1.48M Sell
15,317
-608
-4% -$57.3K 0.93% 37
2017
Q3 		$1.42M Buy
15,925
+82
+0.5% +$6.24K 0.94% 40
2017
Q2 		$1.15M Hold
15,843
– – 0.79% 47
2017
Q1 		$1.03M Buy
15,843
+2,900
+22% +$182K 0.72% 47
2016
Q4 		$810K Hold
12,943
– – 0.67% 54
2016
Q3 		$815K Buy
12,943
+7,843
+154% +$508K 0.71% 48
2016
Q2 		$324K Sell
5,100
-7,793
-60% -$475K 3.29% 10
2016
Q1 		$740K Buy
12,893
+250
+2% +$13.9K 0.68% 46
2015
Q4 		$728K Buy
12,643
+1,643
+15% +$94.6K 0.7% 48
2015
Q3 		$599K Sell
11,000
-900
-8% -$58.6K 0.62% 53
2015
Q2 		$799K Hold
11,900
– – 0.67% 48
2015
Q1 		$696K Buy
11,900
+2,000
+20% +$121K 0.6% 51
2014
Q4 		$647K Buy
+9,900
New +$624K 0.55% 50

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Searle & Co's ABBV Position: Q1 2026 in Review

Searle & Co increased its AbbVie (ABBV) stake by 0.63% in Q1 2026, buying an estimated $66.5K and bringing the position to 48,077 shares worth $10.5M. The position accounts for 2.63% of the portfolio, ranked #6.

Searle & Co first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $11.1M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Searle & Co held 48,077 shares of AbbVie worth $10.5M as of Q1 2026.
  • Searle & Co bought 300 AbbVie shares in Q1 2026, an estimated $66.5K.
  • AbbVie made up 2.63% of Searle & Co's portfolio in Q1 2026, its #6 holding.
  • Searle & Co first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
  • Searle & Co's AbbVie position peaked at $11.1M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Searle & Co's 13F filing for Q1 2026, filed 8 May 2026.